Sivia Capital Partners LLC Makes New Investment in The Clorox Company (NYSE:CLX)

Sivia Capital Partners LLC purchased a new position in shares of The Clorox Company (NYSE:CLX - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm purchased 2,029 shares of the company's stock, valued at approximately $299,000.

A number of other large investors have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Clorox in the 4th quarter valued at about $259,041,000. FMR LLC grew its stake in shares of Clorox by 75.4% in the 4th quarter. FMR LLC now owns 1,361,758 shares of the company's stock valued at $221,163,000 after buying an additional 585,526 shares during the period. Marshall Wace LLP grew its stake in shares of Clorox by 549.8% in the 4th quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock valued at $88,144,000 after buying an additional 459,203 shares during the period. ExodusPoint Capital Management LP grew its stake in shares of Clorox by 187.9% in the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock valued at $113,508,000 after buying an additional 456,114 shares during the period. Finally, Man Group plc grew its stake in shares of Clorox by 154.6% in the 4th quarter. Man Group plc now owns 570,503 shares of the company's stock valued at $92,655,000 after buying an additional 346,449 shares during the period. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Clorox

In other news, Director Pierre R. Breber acquired 4,000 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director now owns 4,000 shares in the company, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.57% of the stock is owned by company insiders.

Clorox Price Performance

Clorox stock opened at $127.71 on Monday. The Clorox Company has a 52 week low of $126.99 and a 52 week high of $171.37. The company's 50 day moving average price is $136.60 and its two-hundred day moving average price is $149.66. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The stock has a market cap of $15.74 billion, a P/E ratio of 34.89, a P/E/G ratio of 2.62 and a beta of 0.54.

Clorox (NYSE:CLX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the prior year, the business earned $1.71 EPS. Clorox's quarterly revenue was down 8.0% compared to the same quarter last year. On average, equities analysts predict that The Clorox Company will post 7.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. UBS Group reduced their target price on Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Morgan Stanley cut their price target on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Evercore ISI set a $140.00 price target on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays cut their price target on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research note on Wednesday, May 7th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $151.23.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.